QIAGEN N.V. reported unaudited second quarter 2026 results on August 5, 2026, with net sales of $535 million, unchanged from the prior year period and exceeding guidance for a 2% decline. Adjusted diluted earnings per share reached $0.62, surpassing the outlook of at least $0.60, while adjusted operating income margin held steady at 29.4%. The company reaffirmed its full-year 2026 outlook for net sales growth of approximately 1-2% and adjusted diluted EPS of at least $2.43 on a constant currency basis. QIAGEN also announced a 40% increase in its annual dividend compared to 2025 levels, with the payment made in July 2026. The company operates in the life sciences and molecular diagnostics industry, providing sample-to-insight solutions for extracting and analyzing biological information.
